Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:41 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Imatinib Mesylate and Zoledronic Acid in Patients With Chronic Myeloid Leukaemia in Cytogenetic Response Without Molecular Response
NCT00210119 · Institut Bergonié · PHASE2 · terminated · last registry update 2021-11-08 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Institut Bergonié |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ABL1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-10-31Phase 3 first posted: Merck Sharp & Dohme LLC, favezelimab/pembrolizumab + regorafenib (NCT05600309)
- 2022-07-18Phase 3 first posted: Centre Hospitalier Universitaire de Besancon, Regorafenib + Metronomic chemotherapies (NCT05462613)
- 2022-07-13Phase 3 first posted: Novartis Pharmaceuticals, Asciminib + Nilotinib (NCT05456191)
- 2022-06-21Phase 3 first posted: Exelixis, XL092 + Atezolizumab (NCT05425940)
- 2022-06-10Phase 3 first posted: Sarit Assouline, Asciminib + Imatinib (NCT05413915)
- 2022-05-02Results posted on the registry: M.D. Anderson Cancer Center, Cyclophosphamide + Cytarabine (NCT02420717)
- 2022-04-27Results posted on the registry: City of Hope Medical Center, carboplatin + dasatinib (NCT00788125)
- 2022-04-15Results posted on the registry: Incyte Corporation, Ruxolitinib + Extracorporeal photopheresis (ECP) (NCT03112603)
- 2022-04-14Phase 3 first posted: Bristol-Myers Squibb, Nivolumab-relatlimab FDC + Regorafenib (NCT05328908)
- 2022-02-15Results posted on the registry: Novartis Pharmaceuticals, Asciminib + Bosutinib (NCT03106779)
- 2022-01-20Phase 3 first posted: Amgen, Sotorasib + Panitumumab (NCT05198934)
- 2021-10-01Phase 3 first posted: Merck Sharp & Dohme LLC, favezelimab/pembrolizumab + regorafenib (NCT05064059)
- 2021-07-21Phase 3 first posted: Novartis Pharmaceuticals, Imatinib + Nilotinib (NCT04971226)
- 2021-07-01Phase 3 first posted: Novartis Pharmaceuticals, ABL001 40mg BID + ABL001 80mg QD (NCT04948333)
- 2021-06-14Results posted on the registry: Takeda, Ponatinib (NCT02467270)
- 2021-05-10Phase 3 first posted: Australasian Gastro-Intestinal Trials Group, Regorafenib + Nivolumab (NCT04879368)
- 2021-03-02Phase 3 first posted: Translational Research in Oncology, Regorafenib in combination with pembrolizumab (NCT04777851)
- 2021-03-01Phase 3 first posted: Merck Sharp & Dohme LLC, pembrolizumab + lenvatinib (NCT04776148)
- 2021-01-25Phase 3 first posted: Gruppo Italiano Malattie EMatologiche dell'Adulto, Ponatinib + Blinatumomab + Chemotherapy + Imatinib (NCT04722848)
- 2021-01-20Results posted on the registry: Institut Bergonié, PD 0332991 (NCT01907607)
- 2021-01-14Results posted on the registry: Novartis Pharmaceuticals, Nilotinib followed by treatment-free (NCT01784068)
- 2021-01-13Results posted on the registry: Novartis Pharmaceuticals, nilotinib (NCT01698905)
- 2020-12-14Phase 3 first posted: Novartis Pharmaceuticals, ABL001 (NCT04666259)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision